The DOI matches its Crossref record; 6 of the 7 references it cites were found in a registry or an index.
Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination
Open accessAbstract
Serum neutralizing antibodies rapidly appear after SARS-CoV-2 infection 1 and vaccination 2 and are maintained for several months.3,4 The emergence of SARS-CoV-2 variants has raised concerns about the breadth of neutralizingantibody responses.We compared the neutralizing-antibody response to 4 variants in infected and vaccinated individuals to determine how mutations within the spike protein are associated with virus neutralization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“By contrast, using the live-virus FRNT neutralization assay (Fig. 1B and Fig. 2B), titers to WA1 were higher than those to D614G, consistent with previous studies of that assay (19).”
From Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
Widge, A. T., Rouphael, N. G., Jackson, L. A., Anderson, E. J., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2032195 · Cited by 722
Self-citationNeutralizing Activity of BNT162b2-Elicited Serum
Liu, Y., Liu, J., Xia, H., Zhang, X., Fontes-Garfias, C. R., Swanson, K. A., Cai, H., Sarkar, R., Chen, W., Cutler, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2102017 · Cited by 537
Self-citationRapid Generation of Neutralizing Antibody Responses in COVID-19 Patients
Suthar, M. S., Zimmerman, M. G., Kauffman, R. C., Mantus, G., Linderman, S. L., Hudson, W. H., Vanderheiden, A., Nyhoff, L., Davis, C. W., Adekunle, O., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100040 · Cited by 508
Self-citationVanderheiden, A., Edara, V. V., Floyd, K. A., Kauffman, R. C., Mantus, G. E., Anderson, E. J., Rouphael, N., Edupuganti, S., Shi, P., Menachery, V. D., et al. (2020) · Current Protocols in Immunology · doi:10.1002/cpim.116 · Cited by 134
Self-citation
Cited by
Sorted by citations
The biological and clinical significance of emerging SARS-CoV-2 variants
Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009
Fiolet, T., Kherabi, Y., MacDonald, C.-J., Ghosn, J., & Peiffer-Smadja, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.005 · Cited by 911
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
Pegu, A., O’Connell, S. E., Schmidt, S. D., O’Dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K. S., et al. (2021) · Science · doi:10.1126/science.abj4176 · Cited by 527
Self-citationKennedy, N. A., Lin, S., Goodhand, J., Chanchlani, N., Hamilton, B., Bewshea, C., Nice, R., Chee, D., Cummings, F. J. R., Fraser, A., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324789 · Cited by 270
The glycosylation in SARS-CoV-2 and its receptor ACE2
Gong, Y., Qin, S., Dai, L., & Tian, Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00809-8 · Cited by 226
Metadata
- Authors
- Edara, V. V., Hudson, W. H., Xie, X., Ahmed, R., & Suthar, M. S.
- Affiliations
- Emory University (US)
- The University of Texas Medical Branch at Galveston (US)
- Corresponding author
- Suthar, Mehul S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2021-05-11
- Volume
- 325
- Issue
- 18
- Pages
- 1896
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC7980146
- OpenAlex
- W3136247297
- Cited by
- 150
- References
- 7
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 9 · 2023: 20 · 2022: 55 · 2021: 51
- FWCI
- 10.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Emory University
- Children's Healthcare of Atlanta
- National Institutes of Health (COVID-19, P51OD011132)
- National Institute on Aging (R00AG049092)
- National Institute of Allergy and Infectious Diseases (COVID-19, R24AI120942, K99AI153736, U19AI090023, R01AI148378, U01AI150747, R01AI127799, UM1AI148684, U19AI057266)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, neutralizing antibodies, SARS-CoV-2 variants, spike protein mutations, vaccine-induced immunity, natural infection, antibody breadth, virus neutralization
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, COVID-19 Serological Testing, Antibodies, Viral, Humans, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
